Rapport Therapeutics (RAPP) Total Liabilities (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Total Liabilities data on file, last reported at $26.1 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 60.85% year-over-year to $26.1 million in Q1 2026; TTM through Mar 2026 was $26.1 million, a 60.85% increase from a year earlier, with the FY2025 full-year figure at $27.8 million, up 192.22% from the prior year.
• Total Liabilities for Q1 2026 stood at $26.1 million, down from $27.8 million in the prior quarter.
• Over the last five years, Total Liabilities for RAPP reached as high as $27.8 million in Q4 2025 and fell as low as $8.0 million in Q3 2024.
• Historically, Total Liabilities has averaged $17.4 million across 4 years, with a median of $16.2 million in 2025.
• Across the five-year window, Total Liabilities sank 34.35% in 2024 and surged 195.22% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $14.5 million in 2023, then slumped by 34.35% to $9.5 million in 2024, then soared by 192.22% to $27.8 million in 2025, then retreated by 6.09% to $26.1 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $26.1 million in Q1 2026, $27.8 million in Q4 2025, and $23.7 million in Q3 2025.